Foghorn Therapeutics Inc. (FHTX) Stock

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.

Foghorn Therapeutics Inc. is led by CEO Adrian H. Gottschalk, employs 112 people, headquartered in US, publicly traded since 2020.

Foghorn Therapeutics Inc. (FHTX) stock trades at $2.00 with a market capitalization of $118.77M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.87, reflecting a net loss over the last twelve months, a negative price-to-book of -1.61, reflecting negative shareholders' equity, price-to-sales of 2.99. Over the past 52 weeks the stock has ranged between $1.79 and $7.61, and currently trades 73.7% below its 52-week high.

On profitability, Foghorn Therapeutics Inc. generates a return on equity (ROE) of 72.64% (not meaningful, as shareholders' equity is negative), return on capital employed of -44.81%, an operating margin of -264.52%, a net profit margin of -175.78%.

Official website: foghorntx.com

Foghorn Therapeutics Inc. by the numbers, 2018–2025

Between 2018 and 2025 Foghorn Therapeutics Inc. reported revenue of $0 rising to $31.0M. Compounded, revenue has grown —% a year over five years, 17.7% over three, 34.8% over the last twelve months. Net profit fell to $-74.0M.

The most recent net margin is -175.78%. On a trailing twelve-month basis to Jun '26, revenue is $36.0M and net profit $-65.0M.

Borrowings rose from $7.0M to $41.0M, cash on hand is $68.0M, cash from operations was $-86.0M in the latest year, positive in 1 of the last 8.

Return on equity has averaged 46.7% over five years, and was 68.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Foghorn Therapeutics Inc. (FHTX) — frequently asked questions